Table 4.

Experimental approaches targeting BTLA/HVEM pathway using antagonistic HVEM-Ig and anti-BTLA mAbs.

Approaches (clone)	Condition	Reported functions [references]
HVEM KO	Autoimmune disease	Increased T cell proliferation and cytokine production 93
HVEM-Ig	Autoimmune disease	Increased T cell proliferation 97
Vaccination + CpG adjuvant	Tumor	Down-regulated BTLA level and decreased BTLA-HVEM-mediated inhibition 98
Anti-BTLA mAb (6A6)	Infection	Reduced the incidence of cerebral malaria 99
Anti-BTLA mAb	Transplantation	Rejected MHC class II-mismatched cardiac allografts 100
Anti-BTLA mAb (6F7) + CTLA-Ig	Transplantation	Prolonged allograft survival 102

s, Soluble; *, the mAbs clone numbers were not given.